{"id":754830,"date":"2023-05-04T08:56:33","date_gmt":"2023-05-04T12:56:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/"},"modified":"2023-05-04T08:56:33","modified_gmt":"2023-05-04T12:56:33","slug":"virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/","title":{"rendered":"Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ATLANTA, Ga., May  04, 2023  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mElHzp6WK9yXkqaH6eyuIRwk-ri--tSxG7qfkVXq6W8woaaTY5FzUtIHPE4JPANq3EgBSxJu1_mz0SlD4RuGDaDJk9myUN7esPAo6MKDC0I=\" rel=\"nofollow noopener\" target=\"_blank\">Virios Therapeutics, Inc.<\/a> (Nasdaq: <strong>VIRI<\/strong>) (the \u201cCompany\u201d), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fTtxHtHGqigTHGEI_hOqLUkgVBCJL5pHuPJ0hdmy_buYRCuTVDNa6G8OdE5mmmzIHZS9Qi2wGbEyTF35pBLSuK4Ozi4iHFjPWP-SPk1RZhQ=\" rel=\"nofollow noopener\" target=\"_blank\">fibromyalgia<\/a> (\u201cFM\u201d), today announced that it will report first quarter 2023 financial results on Thursday, May 11, 2023 before the open of the financial markets.<\/p>\n<p align=\"justify\">\n        <strong>About Virios Therapeutics <\/strong>\n      <\/p>\n<p align=\"justify\">Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fTtxHtHGqigTHGEI_hOqLV3vbBSXImDGCwoMWroLjTfgCea9RoIE4i1qTG71ECe9nL_KinmdQyOtEhpSdQTgdlucM5U7WLWMhxHuWD1ps8s=\" rel=\"nofollow noopener\" target=\"_blank\">fibromyalgia<\/a> (\u201cFM\u201d). Immune responses related to the activation of tissue resident herpes have been postulated as a potential root cause triggering and\/or sustaining chronic illnesses such as FM, irritable bowel disease, chronic fatigue syndrome and other functional somatic syndromes, all of which are characterized by waxing and waning symptoms with no obvious etiology. Our lead development candidate (\u201cIMC-1\u201d) is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms. IMC-1 has been granted fast track designation by the FDA.<\/p>\n<p align=\"justify\">The Company is pursuing a second development candidate, a combination of valacyclovir and celecoxib, as a potential treatment for managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with Long-COVID, otherwise known as Post-Acute Sequelae of COVID-19 (PASC). The Company has provided the Bateman Horne Center (\u201cBHC\u201d) with an unrestricted investigational grant to conduct this study. BHC is a non-profit, interdisciplinary Center of Excellence advancing the diagnosis and treatment of chronic fatigue disorders, FM, post-viral syndromes, and related comorbidities.<\/p>\n<p align=\"justify\">For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YJmy9lShWUU6xlho72w1JZuH-FWWjb0fDPVOG7zBlDJ9GFDWf_LFEDJhcconoRtIU4bAx4cUMM-1Z7mjtg-8EQ==\" rel=\"nofollow noopener\" target=\"_blank\">www.virios.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Follow Virios Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Email Alerts: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DhnfqsdO5ivCKogNc2dUhpdu6OJ4HfpR1rb7GMYbP3Y4gAvIvZqSuQsHblVNZIYLKPgMYiraemhCpYKM2WOn_mwQeeUpWCFINTionrRXEzLOM2kZ-RNZrIeRq-TqnNyG0j7KndpXTaPX5PCsWaHpTw==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/ir.virios.com\/resources\/email-alerts<\/a><\/p>\n<p align=\"justify\">LinkedIn: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DhnfqsdO5ivCKogNc2dUhmlGGrB91xd8Y9CXINlNLDUiXDkVxhPc3wLDxwPuxiC5NrtxyEJ23PtEj-vDoeVNZowAiTjfTzV-vTkL9hrlRJvBL4luLZL4lUoVYTJafgsEgQGcWKFJNKvsLD2ibYqpnqtyxRoAzW1jE5isfUTD3PM=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.linkedin.com\/company\/viriosbiotech\/<\/a><\/p>\n<p align=\"justify\">Twitter: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DhnfqsdO5ivCKogNc2dUhtQfGqJozmO1n9scuV1hzfEO_yeiRXDHXOgJaKiQYiAzxCt-c5xgrlpTxdmaAptmAu3KXOQP8wPA0Q_H22QIk5hEQ-HnZIhztHtDM1AC2eto\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/twitter.com\/ViriosBiotech<\/a><\/p>\n<p align=\"justify\">Facebook: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DhnfqsdO5ivCKogNc2dUhhZbPIryoXepMBcd1LT1491FVXd4CB5rvrKrMi6wLtUnwQKH8tmv5KnCzE1Sov8fkPPyRh_J1OhShS0fGoJmjiUpBekgLuhT5JIcW8W8DOPCQ6VyTkCjZwsA0zh9D7R4dg==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.facebook.com\/ViriosBiotech\/<\/a><\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Statements in this press release contain \u201cforward-looking statements,\u201d within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201csuggest,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d &#8220;will,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Virios Therapeutics\u2019 current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Virios Therapeutics\u2019 product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled \u201cRisk Factors\u201d in the Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Virios Therapeutics, Inc. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\">\n        <strong>Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NTIDD7rd-BcslaHw6t0AbG0sT_3cFSWwv4okNW7xlpRNUs0mAX1M4LYeKO89spj0dan8n-bRDVqSZfuIoq_Fgg==\" rel=\"nofollow noopener\" target=\"_blank\">IR@Virios.com<\/a>\n      <\/p>\n<p align=\"justify\">Source: Virios Therapeutics, Inc. (VIRI)<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQzNCM1NTczNzE3IzIyMDM5OTQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDFmNmNjNjItMDQ4OC00YTlkLTg4OGEtMDE3YTNkODM1YzI1LTEyMTU1NDc=\/tiny\/Virios-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ATLANTA, Ga., May 04, 2023 (GLOBE NEWSWIRE) &#8212; Virios Therapeutics, Inc. (Nasdaq: VIRI) (the \u201cCompany\u201d), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (\u201cFM\u201d), today announced that it will report first quarter 2023 financial results on Thursday, May 11, 2023 before the open of the financial markets. About Virios Therapeutics Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as\u00a0fibromyalgia (\u201cFM\u201d). Immune responses related to the activation of tissue resident herpes have been postulated as a potential root cause triggering and\/or sustaining chronic illnesses such as FM, irritable bowel disease, chronic fatigue syndrome and other functional somatic syndromes, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-754830","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ATLANTA, Ga., May 04, 2023 (GLOBE NEWSWIRE) &#8212; Virios Therapeutics, Inc. (Nasdaq: VIRI) (the \u201cCompany\u201d), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (\u201cFM\u201d), today announced that it will report first quarter 2023 financial results on Thursday, May 11, 2023 before the open of the financial markets. About Virios Therapeutics Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as\u00a0fibromyalgia (\u201cFM\u201d). Immune responses related to the activation of tissue resident herpes have been postulated as a potential root cause triggering and\/or sustaining chronic illnesses such as FM, irritable bowel disease, chronic fatigue syndrome and other functional somatic syndromes, &hellip; Continue reading &quot;Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-04T12:56:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQzNCM1NTczNzE3IzIyMDM5OTQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023\",\"datePublished\":\"2023-05-04T12:56:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\\\/\"},\"wordCount\":541,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTQzNCM1NTczNzE3IzIyMDM5OTQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\\\/\",\"name\":\"Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTQzNCM1NTczNzE3IzIyMDM5OTQ=\",\"datePublished\":\"2023-05-04T12:56:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTQzNCM1NTczNzE3IzIyMDM5OTQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMTQzNCM1NTczNzE3IzIyMDM5OTQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/","og_locale":"en_US","og_type":"article","og_title":"Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 - Market Newsdesk","og_description":"ATLANTA, Ga., May 04, 2023 (GLOBE NEWSWIRE) &#8212; Virios Therapeutics, Inc. (Nasdaq: VIRI) (the \u201cCompany\u201d), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (\u201cFM\u201d), today announced that it will report first quarter 2023 financial results on Thursday, May 11, 2023 before the open of the financial markets. About Virios Therapeutics Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as\u00a0fibromyalgia (\u201cFM\u201d). Immune responses related to the activation of tissue resident herpes have been postulated as a potential root cause triggering and\/or sustaining chronic illnesses such as FM, irritable bowel disease, chronic fatigue syndrome and other functional somatic syndromes, &hellip; Continue reading \"Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-04T12:56:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQzNCM1NTczNzE3IzIyMDM5OTQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023","datePublished":"2023-05-04T12:56:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/"},"wordCount":541,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQzNCM1NTczNzE3IzIyMDM5OTQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/","name":"Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQzNCM1NTczNzE3IzIyMDM5OTQ=","datePublished":"2023-05-04T12:56:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQzNCM1NTczNzE3IzIyMDM5OTQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMTQzNCM1NTczNzE3IzIyMDM5OTQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/virios-therapeutics-to-report-first-quarter-2023-financial-results-on-thursday-may-11-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754830","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=754830"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754830\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=754830"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=754830"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=754830"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}